Document Detail

Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
MedLine Citation:
PMID:  16184044     Owner:  NLM     Status:  MEDLINE    
We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.
Kyle Petersen; Mark S Riddle; Lindsay E Jones; Kari J Furtek; Anne R Christensen; Sybil A Tasker; Braden R Hale
Related Documents :
16890644 - Neuromodulatory therapy to improve erectile function recovery outcomes after pelvic sur...
1531894 - Back school programs. the young patient.
22948104 - Developing emergency exercises for hazardous material transportation: process, document...
18204754 - Conservative treatment for transient osteoporosis of the hip in middle-aged women.
23230234 - Cerebral perfusion, oxygenation and metabolism during exercise in young and elderly ind...
16263834 - Effects of high-dose growth hormone on glucose and glycerol metabolism at rest and duri...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  AIDS (London, England)     Volume:  19     ISSN:  0269-9370     ISO Abbreviation:  AIDS     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-09-26     Completed Date:  2006-05-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710219     Medline TA:  AIDS     Country:  England    
Other Details:
Languages:  eng     Pagination:  1700-2     Citation Subset:  IM; X    
National Naval Medical Center, Bethesda, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bilirubin / blood*
Biological Markers / blood
HIV Infections / blood,  drug therapy*,  virology
HIV Protease Inhibitors / therapeutic use*
Middle Aged
Oligopeptides / therapeutic use*
Patient Compliance*
Pyridines / therapeutic use*
Retrospective Studies
Treatment Outcome
Viral Load
Reg. No./Substance:
0/Biological Markers; 0/HIV Protease Inhibitors; 0/Oligopeptides; 0/Pyridines; 198904-31-3/atazanavir; 635-65-4/Bilirubin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of the anti-HIV activity of statins.
Next Document:  Response to hepatitis A vaccine in HIV patients in the HAART era.